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Abstract 12 
Objectives 13 
The study assessed simultaneous pharmacokinetics (PK) and thermal and mechanical antinociception after intramuscular methadone (0.6 mg/kg) 14 
in 10 cats. 15 
Methods 16 
Thermal (TT) and mechanical (MT) threshold testing and blood collection were conducted at baseline and up to 24 hours after administration. 17 
Methadone plasma concentrations were determined by liquid chromatography - tandem mass spectrometry (LC-MS) and PK parameters were 18 
estimated by a non-compartmental method. TT and MT were analysed using ANOVA (P<0.05). Time of maximum plasma concentration (Tmax), 19 
time of onset of antinociception and time of reaching cut out threshold (TT 55 °C; MT 30N) were determined. 20 
Results 21 
TT and MT increased above baseline from 20 to 240 minutes and 5 to 40 minutes respectively after intramuscular administration (P<0.005). 22 
Maximum delta T (measured as TT minus baseline threshold) (mean ± 95%CI) was 7.9 (4.3-11.6) °C at 60 minutes and maximum delta F 23 
(measured as MT minus baseline threshold) was 4.2 (1.6-6.7) Newtons at 45 minutes. Intramuscular methadone concentration-time data 24 
decreased curvilinearly, and gave a clearance estimate of mean 9.1 ml/kg/min (range 5.2-15.7) with median Tmax at 20 minutes (range 5-360). 25 
Conclusions 26 
Intramuscular data followed classical disposition and elimination in all cats. Plasma concentrations after intramuscular administration were 27 
associated with antinociceptive effect including negative hysteresis.  28 
Relevance  29 
These data can be used for devising dosing schedules for methadone in clinical feline practice. 30 
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 47 
Introduction 48 
Methadone is structurally unrelated to other opium-derived analgesics and exists as a racemic mixture. Each enantiomer has a separate mode of 49 
action; the d-isomer noncompetitively antagonizes the NMDA receptor and inhibits norepinephrine reuptake; the l-isomer is a μ-opioid receptor 50 
agonist 1 51 
 52 
There is only one report of the kinetics of methadone data in the cat 2 and no data enabling the relationship between methadone 53 
pharmacokinetics and dynamic endpoints to be assessed. While administration of drugs IV is the most reliable route to ensure full uptake this is 54 
not always practical in a clinical setting, for example, when used as anaesthetic premedication where IV access may not be possible.  The present 55 
study evaluated the kinetics and dynamics of a single dose of intramuscular (IM) methadone (0.6 mg/kg) in the cat.  Thermal and mechanical 56 
thresholds were measured at the same time as blood sampling to 24 hours post-drug administration. The study was undertaken in order to 57 
provide registration data for an indication for use of IM racemic methadone in the cat.   58 
 59 
 60 
Methods 61 
All studies were conducted after approval by the local institutional review board and according to UK Home Office licence; in-life data were 62 
collected in September 2009. 63 
Pharmacokinetics of methadone 64 
Twelve adult neutered cats (3 male, 9 female; identified as M to X; mean weight 4.4, range 2.9-6.1kg; aged 34 months) received methadone (0.6 65 
mg/kg) administered IM into the quadriceps femoris muscle. The day prior to their testing procedure, the cats were anaesthetised with 66 
sevoflurane delivered in oxygen (induction by face mask followed by endotracheal intubation for maintenance). Over-the-needle catheters were 67 
placed in both cephalic veins for ease of access in case non protocol intravenous administration of substances was required during the study and 68 
as a back-up for/ as the main route for blood sampling. A modified Seldinger technique was used to place 5.5cm intravenous (IV) catheters in the 69 
jugular vein in 6 cats (cats O, Q, S, U, V, X) and saphenous vein in 2 cats (cats M,W), the remaining 4 cats (N,P, R, T) were blood sampled 70 
using the second cephalic catheter.  Once the catheter was securely fixed the cats were returned to their holding cages for recovery from 71 
anaesthesia.  On the day of testing, blood samples were withdrawn from the (IV) (jugular, saphenous or cephalic) catheter before and at 5, 20, 72 
40, 60 minutes, and then at 2, 3, 4, 6, 8, 12 and 24 hours after drug dosing. The volume of blood taken was adjusted for each individual cat, such 73 
that over the 24 hour sampling period, the total blood volume taken was < 10% blood volume. An equal volume of 0.9% saline was injected 74 
after each sample was withdrawn. Blood was taken into lithium heparin tubes, and centrifuged (2000g) for 10 minutes.   Plasma was separated 75 
and stored at -20°C for a maximum of 4 months. 76 
 77 
Plasma methadone concentrations were measured at a commercial assay laboratory (Quotient Bioresearch Ltd, Cambs, UK) using liquid 78 
chromatography - tandem mass spectrometry (LC-MS). In the concentration range 0.5 to 150 ng/ mL, the inter- and intra-assay coefficients of 79 
variation were between 0.8 and 4.3%. Plasma methadone concentrations were linear over the range 0.5 to 150 ng/ mL. The limit of detection for 80 
a 1 mL sample was 0.5 ng/ mL. 81 
 82 
The maximum plasma concentration (Cmax) and time of maximum concentration (Tmax were observed values. Pharmacokinetic parameters were 83 
determined by a non-compartmental method 3. Drug-concentration time profiles were subjected to nonlinear least squares regression of at least 84 
three plasma concentrations to calculate the elimination half-life (t1/2z). The area under the concentration-time curve (AUC) was calculated to the 85 
final concentration time point of 24 hours (Ct) by the linear trapezoidal rule. The residual area to infinity was calculated as Ct/kz where z is the 86 
terminal or elimination rate constant. From these values, other kinetic parameters were calculated: apparent clearance (Cl/F) and apparent 87 
volume of distribution during the elimination phase (Vz/F) (which are given as Cl/F and and Vz/F because we do not know the bioavailability (F) 88 
after intramuscular dosing). Two sets of data for (Cl/F) and (Vz/F) are shown in table 1 - per kg body weight and weight independent.   Vz (also 89 
known as Varea) was used rather than Vdss (steady-state volume of distribution) as it is difficult to calculate the latter for the IM route.  90 
 91 
Pharmacodynamics of methadone 92 
Thermal and mechanical nociceptive thresholds threshold were used to determine the dynamic effects of methadone. 93 
Thermal threshold testing. Thermal nociceptive thresholds were measured using a remote (infra-red) controlled system 4. The testing device 94 
(WTT1, Topcat Metrology Ltd) is attached over the cat’s back with a Velcro® and elastic strap.   A small heating and temperature sensing probe 95 
is held against the shaved thorax of the cat with a pressure bladder inside the strap.  The starting skin temperature (SST) is recorded on the 96 
integral display and then the heater activated so that temperature increases at 0.8˚C per second.   At the cat’s response (skin twitch accompanied 97 
by a behavioural response such as head turn, body shift) heating is stopped immediately and the temperature at the response is held on the 98 
display and recorded as the thermal nociceptive threshold (TT). The probe rapidly returns to the starting skin temperature after the heating is 99 
stopped. There is a safety cut out of 55˚C. 100 
Mechanical threshold testing. Mechanical nociceptive thresholds were measured using a silent, pneumatic system (MTT1, Topcat Metrology 101 
Ltd) which employs a rolling diaphragm actuator 5 attached to a forelimb using a Velcro® and elastic bracelet. The actuator was placed on 102 
shaved skin on the dorso-lateral aspect of the forelimb between carpus and elbow. Three hemispherical tipped pins (2.5 mm diameter) held in the 103 
actuator were advanced against the skin at 2 N per second by increasing the pressure in the actuator manually, using an air filled syringe. A cage 104 
mounted set of LED lights guides the rate of inflation (red = too fast, green = too slow, lights off = correct rate). Inflation is terminated as soon 105 
as the cat’s response is seen (leg shake, biting at the leg, picking up the leg) and the force (N) applied by the actuator at this point is held on the 106 
display and recorded as the mechanical nociceptive threshold (MT). There is a safety cut out of 30N. 107 
Four baseline thresholds were recorded at 15 minute intervals before treatment. The mean of these four readings was taken as the baseline TT or 108 
MT. Thereafter TT and MT were measured at each sampling point to 24 hours post-drug administration. The increase in threshold at the various 109 
time points following methadone administration was determined as delta T (calculated as the TT minus the pre-treatment TT for each cat) and 110 
delta F (MT minus the pre-treatment MT). 111 
The same investigator (LS) performed all the TT and MT tests. There was no blinding as this was a single dose study. 112 
Pupil dilation, sedation scores, monitoring of adverse events Pupil dilation and sedation were recorded at each study time-point with 4 point 113 
scores: 114 
Pupil dilation: 1 = constricted, 2 = normal, 3 = partially dilated, 4 = fully dilated. 115 
Sedation: 0 = none, 1 = mild (cat was relaxed, but could be roused and could walk with no ataxia), 2 = moderate (cat was in sternal or lateral 116 
recumbency, but could be roused and had obvious signs of ataxia), 3 = no response to stimulation. 117 
Any other behaviours or adverse events were recorded as and when they occurred. 118 
 119 
Statistical analyses 120 
Repeated measures ANOVA was performed on the mechanical and thermal dynamic data with post hoc Dunnett’s test; p values less than 0.05 121 
were deemed to be statistically significant.  122 
Three indices of methadone’s antinociceptive effect were determined: 123 
. time to achieving peak plasma drug concentration (Tmax) 124 
. time to onset of antinociceptive effect of the drug and the related methadone plasma concentration (Using a conventional method to define 125 
biological references ranges 6, antinociceptive effect in our model was defined as the baseline threshold (mechanical or thermal) plus 2 SD, all 126 
calculated from the grouped data.) 127 
. time to first achieving the cut-off temperature or mechanical pressure. 128 
These data are presented as median and range values unless otherwise stated. 129 
 130 
AUCs for plasma drug concentration and dynamic endpoints delta T and delta F were calculated using the linear trapezoidal method, and were 131 
compared against each other using regression analysis. 132 
 133 
Results 134 
Prior to dosing, most cats had mildly constricted or normal diameter pupils. Administration of IM methadone resulted in profound thermal 135 
antinociception with no side-effects. It caused pupillary dilation which persisted for up to 12 hours, but no detectable sedation. Due to various 136 
issues full data from 2 cats (O and X) could not be collected; for this reason although 12 cats started the study, only data from 10 cats are 137 
presented. 138 
 139 
Kinetics of methadone in the cat 140 
Unless stated otherwise all data presented are mean (SD).  141 
 142 
Following the 0.6 mg/ kg IM dose of methadone, plasma concentration Tmax occurred at 5 to 120 minutes post dosing in 9 of the cats (median 20 143 
minutes) as presented in Table 1. The exception was cat U which is discussed below.  144 
 145 
The Cmax in the 10 cats was 105 (28) ng/mL (range from 54 to 139 ng/mL).  The sensitivity of the assay allowed all cats to have measurable 146 
plasma methadone concentrations to the last sample point of 24 hours. The AUCs to 24 hours and to infinity were 52803 (14885) and 74464 147 
(25142) ng/mL/min respectively. 148 
 149 
Examination of the derived kinetic parameters showed a normal distribution. The estimates for systemic clearance (Cl) and volume of 150 
distribution during the elimination phase (Vz) are shown as a ratio of parameter divided by bioavailability (F) as an estimate for the latter was not 151 
measured or cited in the literature following IM dosing. The disposition data for the 10 cats are shown in Table 1 including the location of the 152 
intravenous catheter for blood smapling. There were no apparent differences seen using one way ANOVA for the main PK values between 153 
animals where blood sampling had been via the cephalic, jugular or saphenous veins. However the present study was not either aimed at or 154 
powered to examine this variation. 155 
 156 
Dynamics of methadone in the cat 157 
The delta values for MT and TT (i.e. threshold minus baseline) are shown in Figures 1a and b. There was no clinically significant change in the 158 
SST over the time period 0-24 hours (variation by less than 1 ºC). The group pre-treatment TT was 43.4 (2.0) ºC. After intramuscular methadone 159 
dosing, the TT increased significantly from 20 minutes to 4 hours. The peak TT was 54.9 (0.3) ºC. The maximum threshold (safety cut out) of 160 
55ºC was reached in nine cats at 22 (33) minutes after treatment and remained at this value for periods between 20 minutes and 2 hours in these 161 
cats.  162 
The maximum delta T values in the individual cats ranged between 8.7 and 14.8 ºC and occurred between 33 and 150 minutes after dosing. 163 
Where cats remained at the same delta T for more than one time point, then the closest study time point to the average was taken. The plasma 164 
methadone concentration at the time of maximum delta T ranged between 46.7 and 104.0 ng/mL.  Thermal threshold Tmax values are difficult to 165 
estimate in the cats that spent a period of time with thresholds that exceeded the cut out temperature. Individual Tmax values (where there is a 166 
range, this indicates the time spent at cut out) were: M 40 minutes; N 40; P 20-120; Q 40-60; R 120; S 20-180; T 40-240; U 120; V 60; W 5-60.  167 
Mechanical thresholds varied significantly over time with MT significantly raised at 5, 20 and 40 minutes compared to baseline. The pre-168 
treatment MT was 8.4 (1.6) N. The largest delta F ranged in the individual cats between 3.2 and 13.2N, and occurred between 5 and 240 minutes 169 
after dosing. The plasma methadone concentration at the time of maximum delta F ranged between 23.4 and 139.0 ng/mL. 170 
The AUC (of delta T over time) for the period 0-1440 minutes was 3772.8 (1436.9) ºC.min for the intramuscular dosing; while the 171 
corresponding AUC (of delta F over time) for the same period was 1769.3 (1375.6) Newtons.min. Correlation analysis between the AUC (of 172 
plasma methadone concentration over time) and AUC (of antinociceptive effects over time) to 1440 minutes (24 hours) post-dosing indicated 173 
significance for the delta T vs. concentration measurement (r = 0.8573) but not for delta F vs. concentration (r = -0.4156). There was no 174 
significant correlation between the AUCs for the two antinociceptive measures (r = -0.2086). 175 
Kinetic-dynamic relationships 176 
When the measures delta T, delta F and plasma methadone concentration were plotted together against time (Figure 2), there was little difference 177 
between kinetic and dynamic profiles. There did not appear to be any significant separation between drug concentration and effect - although the 178 
Tmax (median) was 20 minutes for concentration; 40 min for MT and for TT. 179 
As with most drug responses the plasma concentration-time profile and the effect-time relationship were not in phase and there was an 180 
anticlockwise hysteresis loop (Figure 3). 181 
Both stimulus modalities also showed a dip in response between 360 and 720 minutes (Figure 2). 182 
The plasma drug concentrations associated with the onset of antinociception baseline plus 2 SD ranged between 39.2 and 124 ng/ml for 183 
temperature; and 23.4 and 139 ng/ml for mechanical pressure. The comparable values for the offset of antinociception were 13.9-105 ng/ml and 184 
15.1-102 ng/ml respectively. 185 
  186 
Discussion 187 
Methadone is a synthetic full agonist opioid, but studies have revealed that it also acts on N-methyl-D-aspartate receptors 7 and it has been used 188 
as an alternative to morphine and hydromorphone in human patients with severe pain. Clinically, in cats, methadone is used for analgesia often 189 
administered as part of anaesthetic premedication where it can assist in the production of sedation in combination with tranquilizers or sedatives. 190 
Most comparable clinical studies have used feline ovariohysterectomy as a surgical model with methadone administered with the premedication 191 
and pain/ analgesia scored by a variety of methods including wound palpation and behavioural and physiological observations.  An early study 192 
examined use of methadone 0.5 mg/kg IM where analgesia was reported for 1.5-6 hours from administration of methadone8; a later study with 193 
0.6 mg/kg IM at premedication reported that 18/19 cats has adequate analgesia for the entire study period of 4 hours after surgery and only a 194 
single cat required rescue analgesia after 90 minutes9; a third study using 0.5 mg/kg IM reported good analgesia for the study period of 6 hours 195 
in 6/8 cats with 1/8 requiring rescue analgesic at 4 hours and 1/8 at 5 hours 10. Pre-anaesthetic sedation with acepromazine - methadone 196 
combination was reported to be poor but similar to that seen with acepromazine -  butorphanol combination 10. 197 
 . 198 
 199 
The current study used threshold testing tools to assess antinociception rather than a surgical stimulus to assess pain/ analgesia. The 200 
physiological processes behind a thermal stimulus applied to the thoracic skin or a mechanical stimulus applied to a forelimb are not the same as 201 
the pain caused by surgery so their clinical relevance could be questioned.  However nociceptive threshold testing tools are widely used and 202 
accepted for pain/ analgesia research in laboratory species and in human volunteers. Our study has demonstrated clear differences between the 203 
effects of methadone on the two stimulus modalities of heat and pressure; significant effects on mechanical thresholds were much shorter acting 204 
than those on thermal thresholds. This is not unknown in analgesia research and may be due to a number of factors including device design and / 205 
or different physiological pathways for the two stimuli.  Since the thermal threshold testing tool has already demonstrated similar thermal 206 
antinociceptive profiles compared to the well documented clinical analgesic profile of commonly used opioid analgesics such as buprenorphine 207 
we would suggest that, for whatever reason, the thermal threshold data are more likely to be similar to the clinical profile of methadone than the 208 
mechanical thresholds.     209 
 210 
Comparison of the time-courses of kinetic and dynamic effects of the opioid show a lag time between increasing plasma concentrations and 211 
increase in observable effects. This is in keeping with the site of action of methadone being at opioid receptors in tissues rather than in plasma 212 
(Figure 3); with the lag being the time taken for methadone to move across the blood brain barrier to opioid receptors in the central nervous 213 
system. Many other drugs demonstrate a similar ‘out of phase’ concentration-time and the effect-time relationship. 214 
 215 
Much less individual variation relating to drug disposition was seen in this study compared to previous studies of other opioids (buprenorphine, 216 
morphine and pethidine) in cats 11, 12. Maximum plasma concentration (Cmax) and time of maximum plasma concentration (Tmax) were very 217 
consistent for all cats except for animal U. In this cat there was a late peak in concentration at 360 minutes which could indicate slow absorption 218 
or perhaps injection into a poorly vascularised area of the body. The quadriceps muscle was used as the site of injection and should be well 219 
vascularised but this cat was noticeably fatter than the other cats and hence injection of drug into fat tissue might be associated with a reduced 220 
rate of absorption. 221 
Median plasma Tmax was at 20 minutes. The absorption was less rapid than that seen in a presently unpublished parallel study in dogs (range 5-222 
15 minutes) although prolonged absorption time was seen in dogs when administered a higher dose of 0.5mg kg-1 compared to 0.3 mg kg-1. 223 
Other studies with opioids in cats have demonstrated the plasma Tmax after IM injection were 15, 3, and 10 minutes for morphine, buprenorphine 224 
and pethidine respectively 11 and 21 minutes for butorphanol 13. 225 
Racemic methadone was administered at 0.6 mg/kg IM in the current study and as this was the only route of administration and the cats were not 226 
also administered an IV dose it was not possible to calculate bioavailability (F) which is why our data has been corrected for F.  At the time of 227 
analysis we were not aware of directly measured data for the bioavailability of methadone after IM administration in the cat. Recently published 228 
data 14 gives a value for F of 44.2% after buccal dosing; with the kinetics for a 0.3 mg/kg IV dose being quoted as clearance 7.2 mL/kg/min and 229 
Vz 2.4/kg. Using the area under the curve in their study and applying it to our data, the estimated bioavailability in our study would be between 230 
80 and 85%. From a study in cats where 0.3 mg/kg  methadone was administered IV 2, using their presented data we have calculated the 231 
clearance as 4.3 mL/kg/min and t½ as 278.4 minutes (4.6 hours). The PK values from these 2 studies are comparable with the values we have 232 
reported here (Cl/F = 9.1 (3.3) mL/ kg/min and Vz/F = 7.8 (2.7) L/ kg; t½  = 627.9 minutes (212.2)). 233 
 234 
Although Hedges and colleagues15 found differences in the disposition after buccal administration of buprenorphine in cats depending on the site 235 
of blood sampling, we have not found any significant differences in the systemic clearance of methadone when comparing data from the three 236 
sites used for blood sampling in this study. However the sample size of each group of cats was small, and to examine it further a properly 237 
powered study would be needed. There are also differences in the route of drug dosing (intramuscular vs buccal) between the two studies. 238 
 239 
The plasma methadone pharmacokinetics reported here for the cat resembles those seen in dogs. After IV administration of 0.45 mg/kg racemic 240 
methadone base to greyhounds 16, systemic clearance was 56.0 (9.4) mL/kg/min and Vz was 7.8 (1.9) L/ kg; after administration of 1 mg/ kg IV 241 
to beagles, total body clearance was 24.1 (9.8) mL/kg/min and Vz was 3.7 (1.1) L/ kg 17.  242 
 243 
When reviewing the literature in humans it becomes clear that while there are many published studies, most publications relate to aspects of its 244 
use is as a heroin replacement substance rather than a first line analgesic and therefore the number of pharmacokinetic studies of methadone in 245 
healthy, non-opiate users are limited. There is also a difficulty in making direct comparisons as most animal studies report values adjusted for 246 
bodyweight whereas those in humans do not. Clearance (Cl) adjusted for bioavailability (Cl/F) after oral administration in opiate-naive humans 247 
was 115 mL/min  (data reported as 6.9 L/ hour) and half-life estimates were 33-46 hours 18. In these individuals, weight as a covariable had no 248 
significant relationship to Cl/F and using the median bodyweight, the calculated Cl/F would be about 2 mL/kg/min. Another study 19 reported 249 
mean clearance after a 5mg IV dose as 8.3 L/ hour (138 mL/ min) and after a 10mg oral dose Cl/F = 9.8 L/ hour (163 mL/ min ); adjustment for 250 
mean volunteer weight (84kg) gives a Cl (IV) of 1.6 mL/kg/min and Cl/F (oral) 1.9 mL/kg/min. The estimate for oral bioavailability in this study 251 
was calculated as 86% making Cl (oral) = 2.2 mL/kg/min, and the half-life was reported as 32 and 31 hours in the IV and oral groups 252 
respectively. Terminal half lives in man, however, are substantially greater than in the cat, for example after effectively a 0.05 mg/ kg dose in 253 
humans, the t ½ was 32 hours whereas after 0.6 mg/kg in the cat the t ½ was 10 hours, this might be due to the large Vd in humans. 254 
 255 
A number of studies have investigated plasma concentration with respect to the antinociceptive or analgesic action of methadone in human 256 
subjects; they appear to be similar for acute pain stimuli such as antinociceptive tests and surgery although much higher concentrations were 257 
required for patients with chronic pain 20, 21.  Postoperative minimum analgesic concentrations in humans were 30-33 ng/ml 22 whereas the EC50 258 
(half maximal effective concentration - the concentration of a drug which induces a response halfway between the baseline and maximum) in 8 259 
chronic pain patients (5 with cancer) was 290 ng/ml 20. Our study findings of plasma methadone concentrations for onset (39.2 to 124 ng/ml) and 260 
offset 13.9-105 ng/ml) of thermal antinociception and onset (23.4 to 139 ng/ml) and offset (15.1-102 ng/ml) of mechanical antinociception are 261 
similar to those required in humans for acute pain stimuli.  262 
 263 
Pharmacokinetics can be defined as what the body does with an administered drug and pharmacodynamics as what the drug does to the body.  264 
The aim when investigating potentially useful clinical analgesics is to determine the optimum plasma concentration associated with analgesia, 265 
PK and PD data may then be used to determine optimum route of administration, dose and dosing interval in order to maintain this analgesic 266 
plasma concentration.  In this study, we have shown that the kinetics of a single dose of IM methadone in the cat are similar to that reported in 267 
the dog. Drug uptake is rapid in the cat, but systemic clearance for both species is greater than that reported for man. We have also determined 268 
analgesic plasma concentrations of methadone.  These data may be used in combination to suggest that analgesia from an intramuscular dose of 269 
methadone at 0.6 mg/kg would be expected to provide four hours of analgesia and that the target plasma concentration for onset of analgesia lies 270 
between 40 and 124 ng/ml.     271 
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  313 
Table 1: Pharmacokinetic parameters for 10 cats after IM administration of 0.6mg/kg methadone. Clearance and volume of distribution are 314 
shown as both body weight dependent and independent. Sampling route, Cep = cephalic; Jug = jugular; Sap = saphenous 315 
 316 
cat  sampling Cmax Tmax Cl/F Cl/F t ½ z Vz/F Vz/F AUC24 
  route ng/ml min ml/min ml/kg/min min litres l/kg ng/mL/min 
N Cep 132 20 34 7.9 350 17 4 62446 
P Cep 92 20 54.2 10.1 412 32 6 53642 
R Cep 122 5 26.4 6.3 824 31 7 68647 
T Cep 125 5 30.2 7 416 18 4 41746 
Q Jug 100 120 27.9 5.2 906 36 7 74022 
S Jug 71 40 50.2 12.5 549 40 10 38990 
U Jug 54 360 40.3 8.6 894 52 11 44206 
V Jug 139 40 25.8 6.1 801 30 7 69644 
M Sap 92 20 45.4 15.7 513 34 12 32319 
W Sap 121 20 43.4 11.1 613 38 10 42370 
 mean 105 65 37.8 9.1 628 33 8 52803 
 SD 28 109 10.3 3.3 212 10 3 14885 
 median 111 20 37.1 8.2 581 33 7 48924 
 317 
 318 
 319 
 320 
Figure 1 321 
Delta T (Fig 1a) and delta F (Fig 1b) threshold values for 10 cats after administration of methadone 0.6mg/kg (mean and standard deviation). 322 
Significant differences from baseline thermal threshold from 20 minutes up to and including 4 hours (1a) and from baseline mechanical 323 
threshold at 5, 20 and 40 minutes (1b) 324 
 325 
Fig 1a                                                                                                                                   Fig 1b 326 
 327 
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 336 
Figure 2 337 
Methadone plamsa concentration and changes in mechanical and thermal threshold (delta T and F)  338 
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 346 
Figure 3 plasma concentration-time profile and the effect-time relationship showing anticlockwise hysteresis loop (effect data derived when 347 
concentrations were increasing are called ‘up’ and those when concentrations were decreasing were called ‘down’)   348 
  349 
 350 
